Microtubule modifiers tubulysins, alkaloidal tetrapeptides isolated from myxobacteria culture broths, are among the most potent antimitotic agents known to date (see the structure of tubulysin D in Fig.1 ). With antiproliferative potencies in the picomolar region they represent remarkable leads for the development of new anticancer agents. Wessjohann and co-workers reported an elegant multiple MCR approach to the synthesis of tubugis, tubulysin analogs incorporating a retro-amide functionality in lieu of the acid-and base-labile N,O-acetal ester moiety (Figure 1 ) [5] . The synthesized tetrapeptides were evaluated for cytotoxic activities and found to display subnanomolar potencies similar to the reference compound tubulysin A (Table) . These potencies were superior to the gold standard microtubule-modifying agent Taxol. This work serves as an excellent illustration of the power of MCR strategies wherein structurally complex alkaloid-inspired tetrapeptides possessing picomolar antiproliferative activities are synthesized in the most straightforward fashion by an intelligent application of a multiple MCR sequence. GI A cytotoxic alkaloid luotonin A ( Fig.2 ) was isolated from the Chinese medicinal plant Peganum nigellastrum and found to display promising anti-topoisomerase I activity. In an attempt to explore its anticancer potential many syntheses of luotonin A have been developed, but because of its topologically challenging structure they involved lengthy sequences and low overall yields. In a groundbreaking contribution to this area of research, Chu and co-workers developed an MCR approach that allows one to synthesize luotonin A and a number of its analogs 4, 5 in one step from commercially available materials [6] . The MCR approach is based on reacting isatoic anhydride with propargylamine followed by the addition of aniline, Yb(OTf) 3 , and glyoxal and refluxing this mixture in o-xylene to furnish luotonin A in 35% yield [6] . A plausible mechanism for this astounding transformation involves a Lewis acid-catalyzed inverse electron demand aza-Diels-Alder reaction of imine 8 to give fully assembled heterocycle 9 followed by its oxidation to the final product luotonin A.
To obtain luotonin A analogs using this MCR, substituted anilines (to obtain compounds 4a-f) or homopropargylamine (to obtain compounds 5a-e) were used with equal success [6] . The evaluation of the synthesized analogs in a topoisomerase I inhibition assay revealed that heterocycles 4c,d and 5b exhibited more potent activities than luotonin A or the well-known topoisomerase I poison camptothecin. Thus, this simple and effective MCR approach will undoubtedly allow for the generation of ample systematic SAR data and lead to novel anti-topoisomerase I agents potentially useful in the treatment of cancer. With a focus on pyrrole-containing biologically active alkaloids, our group has developed a series of MCRs leading to the preparation of diversely substituted pyrroles. Thus, we showed that pentasubstituted pyrroles 11 can be prepared by reacting various sulfonamidoacetophenones 10 with aldehydes and active methylene compounds with the subsequent oxidation of the intermediate pyrrolines with DDQ [7] . In addition, if the mixture of these three components is treated with ethanolic K 2 CO 3 , the reaction proceeds via sulfonyl elimination and provides tetrasubstituted pyrroles 12.
We utilized the latter MCR in the synthesis of marine alkaloids rigidins A, B, C, and D, isolated from tunicates obtained near Okinawa and New Guinea [7] . To this end, commercially available aminoacetophenones 13 are converted to the corresponding sulfonamides, which are then condensed with the requisite aldehydes and cyanoacetamide in the presence of K 2 CO 3 to give tetrasubstituted pyrroles 14. The pyrimidinedione ring closure with oxalyl chloride leads to compounds 15, which are hydrogenolyzed to give rigidins A, B, C, and D in 61, 58, 60, and 53% overall yields, respectively.
Rigidins display antiproliferative and calmodulin antagonistic properties, but their detailed biological evaluation has been hampered by the extremely small quantities of material available from isolation. Several previous synthetic approaches to the rigidin skeleton allowed for the synthesis of rigidin A only and proceeded in 7-9 steps with 13-26% overall yields. Our approach, general for all natural rigidins and highly suitable for the preparation of rigidin analogs, involves only four steps and provides the target molecules in 50-60% overall yields [7] . Studies to utilize this synthetic discovery for the medicinal exploration of the rigidin skeleton are underway.
The naphthyridinomycin family of tetrahydroisoquinoline antibiotics have attracted a considerable attention due to their antimigratory properties and a potential usefulness in the treatment of cancer metastases. The limited availability of these structurally complex alkaloids has plagued their therapeutic development and resulted in a flurry of synthetic activity leading to many total syntheses, for the most part lacking efficiency and generality. Garner and co-workers offered a powerful solution to this problem by reporting a concise total synthesis of cyanocycline A, a representative of this group of alkaloids, based on an asymmetric [C + NC + CC] multicomponent coupling [8] . This MCR of glycyl sultam 21, aldehyde 20, and methyl acrylate is based on an in situ generation of an azomethine ylide from 20 and 21 and its subsequent reaction with the dipolarophile to yield the stereochemically complex pyrrolidine 19 in 73% yield as a 4:1 mixture with an unwanted stereoisomer.
This successful synthesis of cyanocycline A illustrates the power of an asymmetric MCR in a complex synthetic setting and demonstrates that such approaches can be successful even with highly stereochemically challenging targets. This research also led to the discovery that intermediate 16 inhibited cell migration in a different manner by binding to galectin-3, identifying a new therapeutic target previously not associated with cell migration. Clearly, further biological discoveries and a possible therapeutic development of compounds of this class of alkaloids are now facilitated through this efficient MCR approach.
We believe these examples demonstrating the power of the MCR-based approaches in the synthesis of alkaloids and their medicinally important analogs represent an important paradigm shift in alkaloid-based drug discovery. The ''MCR way of thinking'' is entering the natural product synthetic and medicinal programs by offering short and versatile synthetic approaches to complex structures. These feats are becoming increasingly more relevant due to the renewed interest in natural products from the pharmaceutical industry and to the failure of alternative methods to deliver many therapeutic lead compounds.
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